Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $85,554.36 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the sale, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. The trade was a 6.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Mirum Pharmaceuticals Trading Down 1.6 %

NASDAQ MIRM opened at $41.32 on Friday. The company’s 50-day simple moving average is $42.95 and its two-hundred day simple moving average is $40.66. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $48.89. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -20.46 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.57) earnings per share. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Quest Partners LLC raised its holdings in Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after purchasing an additional 1,127 shares in the last quarter. Amalgamated Bank grew its position in shares of Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after buying an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares in the last quarter. ProShare Advisors LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at approximately $213,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $215,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MIRM. Leerink Partners raised their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Citigroup upped their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.